| 000 | 08390nam a22004571i 4500 | ||
|---|---|---|---|
| 003 | EG-GICUC | ||
| 005 | 20251225183100.0 | ||
| 008 | 251225s2025 ua a|||frm||| 000 0 eng d | ||
| 040 |
_aEG-GICUC _beng _cEG-GICUC _dEG-GICUC _erda |
||
| 041 | 0 |
_aeng _beng _bara |
|
| 049 | _aDeposit | ||
| 082 | 0 | 4 | _a618.92994 |
| 092 |
_a618.92994 _221 |
||
| 097 | _aPh.D | ||
| 099 | _aCai01.19.05.Ph.D.2025.Sa.C | ||
| 100 | 0 |
_aSally Mahfouz Abd-Elnaby, _epreparation. |
|
| 245 | 1 | 0 |
_aClinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae (c r e) single institutional experience Egypt. Clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae (CRE) : _bsingle institutional experience, Egypt / _cby Sally M ahfouz Abd-Elnaby ; Supervision Prof. Dr. Lobna Mohammed Shalaby, Prof. Dr. Youssef M adney Saed, Prof. Dr. Mervat Elanany, Dr. Nora Atef Gouda. |
| 246 | 1 | 5 | _aعلم الاوبئة السريرية والجزيئية للبكتريا المعوية المقاومة للكاربابينيم تجربة مؤسسية واحدة بمصر |
| 264 | 0 | _c2025. | |
| 300 |
_a102 pages : _billustrations ; _c25 cm. + _eCD. |
||
| 336 |
_atext _2rda content |
||
| 337 |
_aUnmediated _2rdamedia |
||
| 338 |
_avolume _2rdacarrier |
||
| 502 | _aThesis (Ph.D)-Cairo University, 2025. | ||
| 504 | _aBibliography: pages 85-102. | ||
| 520 | 3 | _aBackground: The rapid worldwide spread of carbapenem-resistant Enterobacteriaceae (CRE) constitutes a major challenge. CRE carrying additional resistance genes to multiple antibiotic classes has created a generation of organisms nearly resistant to all available therapies. CRE infections are associated with significant morbidity and mortality worldwide. This study aims to define the clinical burden of CRE bloodstream infections (BSI), investigate predictors of poor outcomes and risk factors for acquiring CRE BSI, and describe their phenotypic and genotypic characteristics. Methods: This prospective study included Children under 18 years of age with positive blood culture for an Enterobacteriaceae (carbapenem-resistant phenotype [CRE] or carbapenem- VHQVLWLYHSKHQRW\SH>&6(@DWDFKLOGUHQ¶VFDQFHUKRVSLWDOLQ(J\SW±2021) with adopting antimicrobial stewardship program goals and introduction of PCR-based method (Cepheid XpertCarba-R assay) which is developed for detecting carbapenemase genes with the availability of results within one hour which can allow for rapid time to start active treatment in less than 48h. Results: The study focused on pediatric patients with positive blood cultures for Enterobacteriaceae, specifically those with either carbapenem-resistant (CRE) or carbapenem- sensitive (CSE) phenotypes. The participants were categorized into three groups: the first group included 186 patients with CRE-positive blood cultures, the second group comprised 188 patients with CSE-positive blood cultures, and the final group served as a control with 383 participants. Among the CRE patients, 83% had hematological malignancies, while 17% had solid tumors, with acute myeloid leukemia being the most prevalent hematological malignancy. The primary risk factors for acquiring carbapenem-resistant Enterobacteriaceae (CRE), as opposed to carbapenem-sensitive Enterobacteriaceae (CSE), include prolonged and severe neutropenia (absolute neutrophil count (ANC) below 100), prior exposure to beta-lactam/beta- lactamase inhibitors, recent hospitalizations, invasive procedures within the last 30 days, admissions to intensive care units, and a history of colonization with CRE. Escherichia coli was the most frequently isolated pathogen, accounting for 65% of cases, followed by Klebsiella pneumoniae at 31%. The documented sites of infection included pneumonia (37%), typhlitis (17%), skin and soft tissue infections (48%), and urinary tract infections (11%). Among the CRE patients, 57 exhibited aminoglycoside resistance (30.6%), while quinolone resistance was identified in 147 patients (79.0%). Additionally, colistin resistance was observed in 9 CRE patients (4.8%). The Genotypic profile for CRE in our study reported that class B (71%) with NDM reported in 126/186 (67%) and VIM 8/186 (4%) was the most common carbanamase followed by Oxa-48 in 110/186 (59%) of patients while KPC enzyme reported only in 7/186(3.7%). Time to start active antibiotics were initiated within 48 hours for 89% of the patients, with a clinical cure observed in 67% of cases. Microbiological clearance occurred in less than 7 days for 62 % of patients. Sepsis related to CRE necessitated ICU admission for (26%). The 30-day mortality rate was reported at 31 out of 186 patients (16%). In a multivariate analysis of mortality predictors among patients with carbapenem-resistant Enterobacteriaceae (CRE), several factors were identified to elevate the risk of death significantly. These included a central venous catheter infection, extended hospital stays following infection, prolonged neutropenia after bacteremia, isolation of Klebsiella pneumonia as the causative pathogen, and the presence of the KPC and NDM genes as carbapenemase producers. Conclusion: CRE-BSI is a major threat among pediatric cancer patients in limited-resource countries and is considered a barrier against better outcomes. Antimicrobial stewardship through routine screening for colonization detection and Rapid diagnosis by using gene expert with rapid time to start adequate active antibiotics treatment is associated with improvement of outcome and decreasing mortality. | |
| 520 | 3 | _aالانتشار السريع فى جميع أنحاء العالم للبكتريا المعوية المقاومة للكاربابنيم يشكل تحديا كبيرا . تحمل هذه البكتريا جينات مقاومة اضافية لفئات المضادات الحيوية المتعددة تسببت فى وجود أجيال من الكائنات الحية مقاومة تقريبا لكافة المضادات الحيوية المتاحة. و من المعروف ان الاصابة بهذه البكتريا مرتبطة بأمراض و نسبة وفيات عالية . الهدف من هذه الدراسة هو التحقيق من عوامل الخطر المسببة للاصابة بالبكتريا المعوية المقاومة للكاربابنيم و تحديد تنبؤات الوفيات فى الاطفال نتيجة الاصابة بالبكتريا المعوية المقاومة للكاربابنيم و كذلك تحديد الانماط الجينية المهيمنة للبكتريا المعوية المقاومة للكاربابنيم. للاجابة على الاسئلة المذكورة أعلاه سوف نقوم بتنفيذ دراسة رصدية تحليلية فى مستشفى سرطان الاطفال 57357 على مدى عامين. تشمل الدراسة الاطفال اقل من 18سنة من كلا الجنسين و المصابين بالبكتريا المعوية المقاومة للكاربابنيم و تحديد عوامل الخطر و تحديد تنبؤات الوفيات عند األطفال المصابين بعدوى مجرى الدم و الناجمة عن الاصابة بالبكتريا المعوية المقاومة للكاربابنيم مما سيؤدى الى تدخلات من شأنها أن تقلل من ظهور مسببات المقاومة و سوف توجه الباحثين و العلماء الى وضع استراتيجيات وقائية فعالة والتى قد تحد من انتشار هذه المسببات | |
| 530 | _aIssues also as CD. | ||
| 546 | _aText in English and abstract in Arabic & English. | ||
| 650 | 0 | _aTumors in children | |
| 650 | 0 | _aالأورام عند الأطفال | |
| 653 | 1 |
_aCRE _aRisk factors _acarbapenemase |
|
| 700 | 0 |
_aLobna Mohammed Shalaby _ethesis advisor. |
|
| 700 | 0 |
_aYoussef M adney Saed, _ethesis advisor. |
|
| 700 | 0 |
_aMervat Elanany _ethesis advisor. |
|
| 700 | 0 |
_aNora Atef Gouda _ethesis advisor. |
|
| 900 |
_b01-01-2025 _cLobna Mohammed Shalaby _cYoussef Madney Saed _cMervat Elanany _cNora Atef Gouda. _UCairo University _FNational Cancer Institute _DDepartment of Pediatric Oncology |
||
| 905 | _aShimaa | ||
| 942 |
_2ddc _cTH _e21 _n0 |
||
| 999 | _c177036 | ||